<DOC>
	<DOC>NCT03060980</DOC>
	<brief_summary>A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosis of T2D 3 months prior to the Screening Visit. Body mass index (BMI) between ≥25 to ≤45 kg/m2 at the Screening Visit. Glycosylated hemoglobin A1c (HbA1c) ≥7.5 and ≤10.5%. 5. 6. On a stable (3 months prior to the Screening Visit) treatment regimen of metformin monotherapy of ≥1500 mg/day). History of type 1 diabetes. Prior participation in a clinical study involving ITCA 650. Treatment with any GLP1 receptor agonist (eg, liraglutide, exenatide) within 6 months prior to Screening. History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke. History or evidence of acute or chronic pancreatitis. History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2. Treatment of medications that affect GI motility. History of hypersensitivity to exenatide, empagliflozin, or glimepiride or to one of its excipients. Women that are pregnant, lactating, or planning to become pregnant. Chronic (&gt;10 consecutive days) treatment with systemic corticosteroids within 8 weeks prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>